Spyre Therapeutics, Inc. (SYRE)
NASDAQ·Healthcare·Biotechnology
$68.89
-4.19%
Mkt Cap $4.21B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 19, 2026 | $142.86M | $90.49M | -36.65% | -$0.66 | -$0.70 | -6.06% | — | — |
| Q4 2025 Nov 4, 2025 | — | — | — | -$0.68 | -$0.15 | +77.94% | — | — |
| Q3 2025 Aug 5, 2025 | — | — | — | -$0.73 | -$0.49 | +32.88% | — | — |
| Q2 2025 May 8, 2025 | — | — | — | -$0.76 | -$0.74 | +2.63% | — | — |
| Q1 2025 Feb 27, 2025 | $4.00M | — | — | -$0.89 | -$0.81 | +8.99% | — | — |
| Q4 2024 Nov 7, 2024 | $2.63M | — | — | -$0.80 | -$1.36 | -70.00% | — | — |
| Q3 2024 Aug 7, 2024 | $4.00M | — | — | -$0.90 | -$0.86 | +4.44% | — | — |
| Q2 2024 May 9, 2024 | — | — | — | -$0.90 | -$1.20 | -33.33% | — | — |
| Q1 2024 Feb 29, 2024 | $220.00K | $1.04M | +373.64% | -$0.48 | -$2.28 | -375.00% | — | — |
| Q4 2023 Nov 9, 2023 | $198.00K | — | — | -$0.84 | -$9.34 | -1011.90% | — | — |
| Q3 2023 Aug 11, 2023 | $198.00K | $688.00K | +247.47% | -$4.50 | -$1.66 | +63.11% | — | — |
| Q1 2023 Mar 31, 2023 | $184.00K | $198.00K | +7.61% | -$4.50 | -$4.89 | -8.57% | — | — |
| Q4 2022 Dec 30, 2022 | $133.33K | $168.00K | +26.00% | -$5.71 | -$7.20 | -26.14% | — | — |
| Q3 2022 Sep 29, 2022 | $208.33K | $174.00K | -16.48% | -$6.25 | -$4.84 | +22.57% | — | — |
| Q2 2022 Jun 29, 2022 | $709.50K | $625.00K | -11.91% | -$7.95 | -$6.79 | +14.57% | — | — |
| Q1 2022 Mar 30, 2022 | — | $1.36M | — | — | -$9.26 | — | — | — |
| Q4 2021 Dec 30, 2021 | $1.59M | $3.64M | +128.84% | -$8.54 | -$10.36 | -21.33% | — | — |
| Q3 2021 Sep 29, 2021 | — | $1.40M | — | — | -$7.72 | — | — | — |
| Q2 2021 Jun 29, 2021 | — | $13.70M | — | — | -$2.60 | — | — | — |
| Q1 2021 Mar 31, 2021 | — | — | — | — | -$6.94 | — | — | — |